The U.S. Patent and Trademark Office (USPTO) has granted a Notice of Allowance to Tranzyme Pharma for its patent application entitled "Combinatorial Synthesis of Libraries of Macrocyclic Compounds."
The patent protects key aspects of the Company's core drug-design platform, Macrocyclic Template Chemistry (MATCH™).
MATCH™ is a proprietary drug design and medicinal chemistry technology which exploits a distinct compound class, macrocyclic small molecules. Tranzyme has developed the first synthetic library of these macrocyclic small molecules. MATCH™ has proven to be a particularly rich source for novel drug candidates since it maintains the favorable characteristics exhibited by large biomolecules, such as tight receptor binding for high potency and selectivity, while eliminating the drawbacks typically associated with peptide and protein drugs, i.e. poor metabolic stability, low oral bioavailability, lack of membrane permeability, high manufacturing costs, and antigenicity.
Tranzyme Pharma employs MATCH in the discovery and development of drugs for the treatment of gastrointestinal (GI) and metabolic diseases.
For more information, see Tranzyme's press release.
.jpg)
Comment Preview